title: Characterization of lidocaine-specific T cells.
abstract: To investigate the cellular immune response to the drug lidocaine, we generated T cell lines and clones from the peripheral blood of four patients with proven allergy to lidocaine. The patients had contact dermatitis after topical application of lidocaine, and local swelling or generalized erythema exudativum multiforme after submucosal/subcutaneous injection of lidocaine. Two of three lidocaine-specific T cell lines were oligoclonal and one even became monoclonal, while the simultaneously analyzed immune response to tetanus toxoid was polyclonal. The lidocaine-specific T cell lines cross-reacted to mepivacaine, but not to other local anesthetics (bupivacaine, procaine, oxybuprocaine, and tetracaine). The majority of reactive T cells belonged to the CD4 cell lineage and were MHC class II restricted, but cloning also revealed some MHC class I-restricted CD8+ clones. A total of 2 of 56 lidocaine-specific T cell clones were CD4-CD8- and expressed TCR-gammadelta. The majority of 13 analyzed CD4 clones produced a rather polarized cytokine pattern, with a dominance of Th2-like cytokines showing a high IL-5 production. In addition, three CD4+ and all CD8+ (n = 7) clones secreted high IFN-gamma and low levels of IL-5/IL-4 (Th1-like). The data illustrate that a drug that sensitizes via the skin elicits a heterogeneous T cell response. The high IL-5 production and the participation of specific CD4+CD8+ and even gammadelta+ T cells appear to be distinguishing features of this hapten-specific immune response.
authors.affiliation: Institute of Immunology and Allergology, Inselspital, Bern, Switzerland.
authors.forename: M P
authors.initials: MP
authors.lastname: Zanni
authors.forename: D
authors.initials: D
authors.lastname: Mauri-Hellweg
authors.forename: C
authors.initials: C
authors.lastname: Brander
authors.forename: T
authors.initials: T
authors.lastname: Wendland
authors.forename: B
authors.initials: B
authors.lastname: Schnyder
authors.forename: E
authors.initials: E
authors.lastname: Frei
authors.forename: S
authors.initials: S
authors.lastname: von Greyerz
authors.forename: A
authors.initials: A
authors.lastname: Bircher
authors.forename: W J
authors.initials: WJ
authors.lastname: Pichler
mesh_terms: D000328:Adult; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002478:Cells, Cultured; D002999:Clone Cells; D003429:Cross Reactions; D003877:Dermatitis, Contact / Q000276:immunology; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis; D015847:Interleukin-4 / Q000096:biosynthesis; D015848:Interleukin-5 / Q000096:biosynthesis; D008012:Lidocaine / Q000737:chemistry / Q000276:immunology*; D008213:Lymphocyte Activation; D008297:Male; D008619:Mepivacaine / Q000276:immunology; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000276:immunology; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000032:analysis; D016176:T-Lymphocyte Subsets / Q000276:immunology*
chemical_list: D006680:HLA Antigens; D015848:Interleukin-5; D016693:Receptors, Antigen, T-Cell, alpha-beta; D016692:Receptors, Antigen, T-Cell, gamma-delta; D015847:Interleukin-4; D007371:Interferon-gamma; D008012:Lidocaine; D008619:Mepivacaine